Maria Raptis

Ms. Raptis concentrates her practice on representing clients before the Federal Trade Commission (FTC) and Department of Justice. She has advised clients in a broad range of strategic transactions across multiple industries, including health care and pharmaceuticals, technology, consumer products, entertainment and manufacturing. Ms. Raptis has been named to Chambers USA, in which clients say she is a “great business partner, incredibly responsive and highly in-tune to the general market.” She also has been named among North America’s Top Antitrust Lawyers and Top Female M&A Lawyers by MergerLinks, and has been recognized by Who’s Who Legal: Competition. Some of her significant representations include:

• Activision Blizzard Inc. in its pending $75 billion acquisition by Microsoft Corporation;
• Xilinx, Inc. in its $49 billion acquisition by Advanced Micro Devices, Inc.;
• Livongo Health in its $18.5 billion sale to Teladoc;
• Visa Inc. in its proposed but terminated $5.3 billion acquisition of Plaid Inc.;
• ZeniMax Media Inc. in its pending $7.5 billion acquisition by Microsoft Corporation;
• Array BioPharma in its $11.4 billion acquisition by Pfizer;
• Gilead Sciences, Inc. in its $4.9 billion acquisition of Forty Seven, its $5.1 billion 10-year global research and development collaboration and equity investment in Galapagos NV, its $11.9 billion acquisition of Kite Pharma, Inc., its $11 billion acquisition of Pharmasset and its acquisition of Cell Design Labs for up to $567 million;
• PayPal in its $4 billion acquisition of Honey Science Corporation and its strategic investments in MercadoLibre, Inc. and Uber Technologies, Inc.;
• Pandion Therapeutics in its sale to Merck for $1.8 billion;
• MorphoSys in its $1.7 billion acquisition of Constellation Pharmaceuticals and its related financing from Royalty Pharma totaling over $2 billion;
• Realogy Holdings Corp. in the proposed $400 million sale of its global Cartus Relocation business to SIRVA Worldwide, Inc.;
• Achillion Pharmaceuticals, Inc. in its $930 million acquisition by Alexion Pharmaceuticals, Inc.;
• First Bancorp. in its $1.1 billion acquisition of Banco Santander S.A.'s (Spain) Puerto Rico banking operations;
• NXP Semiconductors N.V. in its proposed but terminated $47 billion acquisition by Qualcomm Incorporated;
• Hewlett Packard Enterprise Co. in its $1.3 billion acquisition of Cray Inc. and its $1 billion acquisition of Samsung's printing business;
• Intel Corporation in numerous transactions, including its $15.3 billion acquisition of Mobileye N.V. and its $1 billion sale of its modem business to Apple;
• Ionis Pharmaceuticals in its acquisition of the remaining outstanding stake of Akcea Therapeutics for $500 million;
• CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to $939.5 million;
• Stemline Therapeutics in its sale to Menarini Group for up to $677 million;
• Airbnb in its $400 million acquisition of Hotel Tonight;
• Carbonite, Inc. in its $1.4 billion acquisition by Open Text Corporation;
• Sophos Group plc with U.S. aspects of its $3.9 billion acquisition by Thoma Bravo, LLC;
• ArQule in its sale to Merck for $2.7 billion;
• Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion;
• TiVo Inc. in its $1.1 billion acquisition by Rovi Corporation;
• SanDisk in its $19 billion acquisition by Western Digital;
• Actavis in its $28 billion acquisition of Forest Laboratories and its $8.5 billion acquisition of Warner Chilcott;
• Cineworld Group PLC in its $5.9 billion acquisition of Regal Entertainment Group;
• Juno Therapeutics, Inc. in its $11 billion acquisition by Celgene Corporation;
• Valeant in its acquisitions of Salix, Medicis, Dermik, Ortho Dermatologics and Biovail;
• Watson in its $5.9 billion acquisition of Actavis and its $1.9 billion acquisition of Andrx;
• NDS Group in its $5 billion acquisition by Cisco Systems;
• Clementia Pharmaceuticals in its sale to Ipsen for up to $1.31 billion;
• Nightstar Therapeutics in its $800 million sale to Biogen;
• Synergy Pharmaceuticals in its Chapter 11 filing and proposed sale of assets to Bausch Health for $200 million;
• Strongbridge Biopharma in its merger with Xeris Pharmaceuticals, as well as its sale of Macrilen to Novo Nordisk for $145 million plus royalties, and the related $36.7 million equity investment by Novo Nordisk in Strongbridge; and
• Ultragenyx in its successful topping bid for Dimension Therapeutics.

Ms. Raptis' litigation experience includes defending clients in connection with class actions and multidistrict litigations challenging patent settlements, pricing and other business policies, including Actavis in suits brought by the FTC and private plaintiffs relating to "reverse payment" settlements and De Beers in connection with national class actions involving gem diamonds.

Ms. Raptis also has represented clients in connection with allegations of price-fixing and other criminal charges, including De Beers in connection with the resolution of a criminal matter relating to industrial diamonds.